Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Non-regulated
Sequana Medical AG (“Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of a multicentre, randomized controlled trial in the Journal of Hepatology. The study demonstrated that in patients with refractory ascites, the alfapump®: significantly reduces the requirement for LVP compared to standard of...
Read More
The Board of Directors of Sequana Medical AG (“Sequana Medical” or the “Company”) announces with great sadness, the sudden death of its Founder, President and Chief Executive Officer, Noel L. Johnson, Ph. D. Dr. Johnson founded the Company in 2006 and has served as President and Chief Executive Officer since then. Noel originated the idea...
Read More
Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative, implantable pump systems that manage fluid build-up occurring in patients with liver disease, heart disease and certain cancers, announced today the appointment of Ian Crosbie as Chief Financial Officer. “We are delighted to welcome Ian to Sequana Medical....
Read More
Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative, implantable pump systems to manage fluid build-up in patients with liver disease, congestive heart failure and certain cancers, announced today that Rolf A. Classon, former top executive of Bayer AG and Pharmacia AB, has been appointed Chairman of...
Read More
Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative implantable pump systems that manage excess fluid within the body, announced today that it has raised CHF 9 million ($9.3 million) in a Series C extension round. Existing investors including NeoMed Management AS, VI Partners AG, Biomed Invest...
Read More
Sequana Medical was delighted to present the alfapump system for the third time at this year’s nationwide Viszeralmedizin Congress, organised by the DGVS (German Society for Gastroenterology, Digestive and Metabolic Diseases) and the DGAV (German Society for General and Visceral Surgery), held in Leipzig’s CCL Congress Centre. This year, we were proud to organise a...
Read More
1 7 8 9

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES